Business
Grant of Share Options
Grant of Share Options.
About this update from Renalytix Plc
[{"type":"text","content":"\n\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\n \nGrant of Share Options\n \nLONDON and SALT LAKE CITY - November 23, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that the Board have granted options over a total of 380,000 ordinary shares of 0.25 pence each in the capital of the Company (the \"Share Options\") to the following individuals:\n \n\n\n\n\nName\n\n\nPosition\n\n\nOptions granted\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nChristopher Mills\n\n\nNon-Executive Chairman\n\n\n95,000\n\n\n\n\nDaniel Levangie\n\n\nNon-Executive Director\n\n\n95,000\n\n\n\n\nChirag Parikh\n\n\nNon-Executive Director\n\n\n95,000\n\n\n\n\nCatherine Coste\n\n\nNon-Executive Director\n\n\n95,000\n\n\n\n\n \nThe Share Options, which have been issued in line with the Company's existing share option plan, have an exercise price of £0.245 per ordinary share, being the closing price of the shares on the 17 November 2023. \n \nAll the Share Options granted one twelfth of the Share Options vest 3 months from the date of grant with one twelfth vesting quarterly after that, subject to the individuals remaining employed by the Company as Non-Executive Directors.\n \nThe issue of the Share Options are deemed to be related party transactions pursuant to AIM Rule 13 of the AIM Rules for Companies. The Company's directors (excluding those who are being awarded the Share Options) consider, having consulted with the Nominated Adviser, Stifel Nicolaus Europe Limited, that the terms of the related party transactions are fair and reasonable insofar as the shareholders of the Company are concerned.\n \nFor further information, please contact:\n \n\n\n\n\nRenalytix plc\n\n\nwww.renalytix.com\n\n\n\n\nJames McCullough, CEO\n\n\nVia Walbrook PR\n\n\n\n\n\n\n\n \n\n\n\n\nStifel (Nominated Adviser, Joint Broker)\n\n\nTel: 020 7710 7600\n\n\n\n\nAlex Price / Nicholas Moore / Nick Harland / Samira Essebiyea\n\n\n \n\n\n\n\n\n\n\n \n\n\n\n\nInvestec Bank plc (Joint Broker)\n\n\nTel: 020 7597 4000\n\n\n\n\nGary Clarence / Shalin Bhamra\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Limited\n\n\nTel: 020 7933 8780 or...